Overview

ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The study is designed to investigate the activity of the hormone drug leuprolide acetate in stabilizing cognitive function in mild-to-moderate AD patients.
Phase:
Phase 3
Details
Lead Sponsor:
Voyager Pharmaceutical Corporation
Treatments:
Leuprolide